- IN₹705.20bn
- IN₹721.12bn
- IN₹166.42bn
- 89
- 13
- 100
- 81
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 30.94 | ||
| PEG Ratio (f) | 1.97 | ||
| EPS Growth (f) | 18.65% | ||
| Dividend Yield (f) | 0.51% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.33 | ||
| Price to Tang. Book | 8.01 | ||
| Price to Free Cashflow | 37.95 | ||
| Price to Sales | 3.62 | ||
| EV to EBITDA | 21.17 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.54% | ||
| Return on Equity | 14.27% | ||
| Operating Margin | 12.33% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 146,645.6 | 153,747.6 | 151,629.6 | 164,054.8 | 166,416.6 | 198,419.32 | 217,222.63 | 1.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -21.68 | -87.75 | +1248.34 | -80.29 | +83.55 | +336.25 | +18.65 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lupin Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is engaged in the Anti-TB and Cephalosporins segments. The Company along with its subsidiaries has manufacturing locations spread across India, United States of America, Mexico and Brazil with trading and other incidental and related activities extending to the global markets. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol and others. Its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim) and Etanercept. It diabetes brands include ONDERO and ONDERO MET.
Directors
- Manju Gupta NEC
- Vinita Gupta CEO (53)
- Kamal Sharma NVC
- Ramesh Swaminathan CFO (55)
- Debabrata Chakravorty CEX
- Rajendra Chunodkar CEX
- Fabrice Egros CEX
- Naresh Gupta CEX
- Rajender Kamboj CEX
- Cyrus Karkaria CEX
- Yashwant Mahadik CEX (52)
- Sunil Makharia CEX
- Johnny Mikell CEX
- Sofia Mumtaz CEX
- Rajeev Sibal CEX
- Alok Sonig CEX
- Jon Stelzmiller CEX
- Thierry Volle CEX
- Nilesh Gupta MDR
- J. Alan Butcher OTH
- Rajvardhan Satam SEC
- K. B. S. Anand NID
- Jean-Luc Belingard NID
- Punita Kumar-sinha NID
- Mark McDade NID
- Christine Mundkur NID (52)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 1st, 1983
- Public Since
- November 30th, 1994
- No. of Shareholders
- 357,039
- No. of Employees
- 18,971
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 455,750,104
- Address
- B/4 Laxmi Towers, MUMBAI, 400055
- Web
- https://www.lupin.com/
- Phone
- +91 2266402323
- Auditors
- BSR & Co. LLP
Upcoming Events for LUPIN
Q1 2025 Lupin Ltd Earnings Release
Lupin Ltd Annual Shareholders Meeting
Similar to LUPIN
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Lupin share price?
As of Today at 19:13 UTC, shares in Lupin are trading at IN₹1,547.55. This share price information is delayed by 15 minutes.
How has the Lupin share price performed this year?
Shares in Lupin last closed at IN₹1,547.55 and the price had moved by +126.17% over the past 365 days. In terms of relative price strength the Lupin share price has outperformed the S&P BSE 100 Index by +75.42% over the past year.
What are the analyst and broker recommendations for Lupin?
The overall consensus recommendation for Lupin is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Lupin dividend yield?
The Lupin dividend yield is 0.26% based on the trailing twelve month period.
Does Lupin pay a dividend?
Last year, Lupin paid a total dividend of IN₹4.00, and it currently has a trailing dividend yield of 0.26%. We do not have any data on when Lupin is to next pay dividends.
When does Lupin next pay dividends?
We do not have data on when Lupin is to next pay dividends. The historic dividend yield on Lupin shares is currently 0.26%.
How do I buy Lupin shares?
To buy shares in Lupin you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lupin?
As of the previous close price of IN₹1,547.55, shares in Lupin had a market capitalisation of IN₹705.20bn.
Where are Lupin shares listed?
Here are the trading details for Lupin:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: LUPIN
What kind of share is Lupin?
Based on an overall assessment of its quality, value and momentum Lupin is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lupin share price forecast for 2024?
The analyst consensus target price for shares in Lupin is IN₹1,382.81. That is 10.65% below the last closing price of IN₹1,547.55.
Analysts covering Lupin currently have a consensus Earnings Per Share (EPS) forecast of IN₹42.16 for the next financial year.
What is the trend in the Lupin share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lupin. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +12.11%.
As of the last closing price of IN₹1,547.55, shares in Lupin were trading +20.44% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lupin PE Ratio?
The Lupin PE ratio based on its reported earnings over the past 12 months is 30.94. The shares last closed at IN₹1,547.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lupin?
Lupin's management team is headed by:
- Manju Gupta - NEC
- Vinita Gupta - CEO
- Kamal Sharma - NVC
- Ramesh Swaminathan - CFO
- Debabrata Chakravorty - CEX
- Rajendra Chunodkar - CEX
- Fabrice Egros - CEX
- Naresh Gupta - CEX
- Rajender Kamboj - CEX
- Cyrus Karkaria - CEX
- Yashwant Mahadik - CEX
- Sunil Makharia - CEX
- Johnny Mikell - CEX
- Sofia Mumtaz - CEX
- Rajeev Sibal - CEX
- Alok Sonig - CEX
- Jon Stelzmiller - CEX
- Thierry Volle - CEX
- Nilesh Gupta - MDR
- J. Alan Butcher - OTH
- Rajvardhan Satam - SEC
- K. B. S. Anand - NID
- Jean-Luc Belingard - NID
- Punita Kumar-sinha - NID
- Mark McDade - NID
- Christine Mundkur - NID